PearsonGJThompsonAESemchukWS.2007 guidelines for the management of dyslipidemia and prevention of cardiovascular disease by pharmacists. Can Pharm J (Ott)2007;140:383-8.
2.
TurgeonRDAndersonTJGregoireJPearsonGJ.Updated guidelines for the management of dyslipidemia and prevention of cardiovascular disease by pharmacists. Can Pharm J (Ott)2015;148:21-8.
3.
TsuyukiRTRosenthalMPearsonGJ.A randomized trial of a community-based approach to dyslipidemia management: pharmacist prescribing to achieve cholesterol targets (RxACT study). Can Pharm J (Ott)2016;149:283-92.
4.
TsuyukiRTAl HamarnehYNJonesCAHemmelgarnBR.The effectiveness of pharmacist interventions on cardiovascular risk: the multicenter randomized controlled RxEACH trial. J Am Coll Cardiol2016;67:2846-54.
5.
AndersonTJGregoireJPearsonGJ. 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol2016;32:1263-82.
6.
RayJGVermeulenMJSchullMJRedelmeierDACardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet2005;366:1797-803.
7.
Mongraw-ChaffinMLCirilloPMCohnBA.Preeclampsia and cardiovascular disease death: prospective evidence from the child health and development studies cohort. Hypertension2010;56:166-71.
8.
WannerCTonelliM, Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int2014;85:1303-9.
9.
PletcherMJTiceJAPignoneMBrownerWS.Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Arch Intern Med2004;164:1285-92.
10.
WritingCommitteeLloyd-JonesDMMorrisPB. 2016ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology task force on clinical expert consensus documents. J Am Coll Cardiol2016;68:92-125.
11.
PiepoliMFHoesAWAgewallS. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur J Prev Cardiol2016;23:NP1-96.
12.
HovinghGKDavidsonMHKasteleinJJO’ConnorAM.Diagnosis and treatment of familial hypercholesterolemia. Eur Heart J2013;34:962-71.
13.
SidhuDNauglerC.Fasting time and lipid levels in a community-based population: a cross-sectional study. Arch Intern Med2012;172:1707-10.
14.
LangstedAFreibergJJNordestgaardBG.Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins and cardiovascular risk prediction. Circulation2008;118:2047-56.
PalmerSCCraigJCNavaneethanSD. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med2012;157:263-75.
17.
YusufSBoschJDagenaisG. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med2016;374:2021-31.
18.
CannonCPBlazingMAGiuglianoRP. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med2015;372:2387-97.
19.
SabatineMSGiuglianoRPKeechAC. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med2017;376:1713-22.
20.
RobinsinJGFarnierMKrempfM. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med2015;372:1489-99.
21.
SabatineMSGiuglianoRPWiviottSD. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med2015;372:1500-9.
